These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 33150145)

  • 41. Microbiota, NASH, HCC and the potential role of probiotics.
    Brandi G; De Lorenzo S; Candela M; Pantaleo MA; Bellentani S; Tovoli F; Saccoccio G; Biasco G
    Carcinogenesis; 2017 Mar; 38(3):231-240. PubMed ID: 28426878
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
    Bertot LC; Adams LA
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
    Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
    Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fine-tuning of regulatory T cells is indispensable for the metabolic steatosis-related hepatocellular carcinoma: A review.
    Riaz F; Wei P; Pan F
    Front Cell Dev Biol; 2022; 10():949603. PubMed ID: 35912096
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of the microbiome in NAFLD and NASH.
    Kolodziejczyk AA; Zheng D; Shibolet O; Elinav E
    EMBO Mol Med; 2019 Feb; 11(2):. PubMed ID: 30591521
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunomodulation by probiotics and prebiotics in hepatocellular carcinoma.
    Russo E; Fiorindi C; Giudici F; Amedei A
    World J Hepatol; 2022 Feb; 14(2):372-385. PubMed ID: 35317185
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Roles of PPARs in NAFLD: potential therapeutic targets.
    Tailleux A; Wouters K; Staels B
    Biochim Biophys Acta; 2012 May; 1821(5):809-18. PubMed ID: 22056763
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of the Relationship Between the Degree of Dysbiosis in Gut Microbiota and Prognosis at Different Stages of Primary Hepatocellular Carcinoma.
    Ni J; Huang R; Zhou H; Xu X; Li Y; Cao P; Zhong K; Ge M; Chen X; Hou B; Yu M; Peng B; Li Q; Zhang P; Gao Y
    Front Microbiol; 2019; 10():1458. PubMed ID: 31293562
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatocellular Carcinoma: How the Gut Microbiota Contributes to Pathogenesis, Diagnosis, and Therapy.
    Luo W; Guo S; Zhou Y; Zhao J; Wang M; Sang L; Chang B; Wang B
    Front Microbiol; 2022; 13():873160. PubMed ID: 35572649
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.
    Bluemel S; Williams B; Knight R; Schnabl B
    Am J Physiol Gastrointest Liver Physiol; 2016 Dec; 311(6):G1018-G1036. PubMed ID: 27686615
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.
    Marot A; Henrion J; Knebel JF; Moreno C; Deltenre P
    PLoS One; 2017; 12(10):e0186715. PubMed ID: 29077714
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatocellular Cancer and Gut Microbiome: Time to Untie Gordian's Knot.
    Aygün C; Tözün N
    J Gastrointest Cancer; 2021 Dec; 52(4):1309-1313. PubMed ID: 34750696
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
    Boursier J; Diehl AM
    Clin Liver Dis; 2016 May; 20(2):263-75. PubMed ID: 27063268
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.
    Wong CR; Nguyen MH; Lim JK
    World J Gastroenterol; 2016 Oct; 22(37):8294-8303. PubMed ID: 27729736
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States.
    Paik JM; Golabi P; Biswas R; Alqahtani S; Venkatesan C; Younossi ZM
    Hepatol Commun; 2020 Jun; 4(6):890-903. PubMed ID: 32490324
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alterations in the Gut Microbiome in the Progression of Cirrhosis to Hepatocellular Carcinoma.
    Lapidot Y; Amir A; Nosenko R; Uzan-Yulzari A; Veitsman E; Cohen-Ezra O; Davidov Y; Weiss P; Bradichevski T; Segev S; Koren O; Safran M; Ben-Ari Z
    mSystems; 2020 Jun; 5(3):. PubMed ID: 32546668
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.
    Baffy G; Brunt EM; Caldwell SH
    J Hepatol; 2012 Jun; 56(6):1384-91. PubMed ID: 22326465
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage.
    Neuman MG; French SW; Zakhari S; Malnick S; Seitz HK; Cohen LB; Salaspuro M; Voinea-Griffin A; Barasch A; Kirpich IA; Thomes PG; Schrum LW; Donohue TM; Kharbanda KK; Cruz M; Opris M
    Exp Mol Pathol; 2017 Feb; 102(1):162-180. PubMed ID: 28077318
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.
    Ballestri S; Nascimbeni F; Romagnoli D; Baldelli E; Lonardo A
    Adv Ther; 2016 Mar; 33(3):291-319. PubMed ID: 26921205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.